×
Breaking News
INTERNATIONAL THALASSAEMIA DAY 2026 | First Campaign Materials Now Available
TIF WEBINAR SERIES 2026 | Bridging the Communication Gap in Haemoglobinopathy Care
wAIHA | Rilzabrutinib Receives FDA Breakthrough Therapy Designation
INTERNATIONAL THALASSAEMIA DAY 2026 | A New Theme for Global Action
RARE DISEASE DAY 2026 | More Than You Can Imagine
wAIHA | Sovleplenib Demonstrates Positive Phase III Clinical Results
THALASSAEMIA IN THE AMERICAS | New TIF White Paper Calls for Coordinated Action and Equity in Care
THE MENA THALASSAEMIA EXPERIENCE: A Two-Day, In-Person Masterclass
U.S. EXIT FROM WHO | Implications for Global Health Cooperation and Preparedness
SICKLE CELL DISEASE | Alzheimer’s Drug Demonstrates Potential Therapeutic Benefit
Menu
Home
Who we are
TIF History
Vision & Mission
Pillars of Work
Board of Directors
Staff Members
TIF Members
Collaborations
Transparency
Awards & Honours
What we do
Education
Country Work
Projects
Global Thalassaemia Review
COVID-19 Pandemic
Surveys
Haemoglobin Disorders
Thalassaemia
Sickle Cell Disease
Other Anaemias
Clinical Trial Updates
Positions & Policies
Policy Framework
Position Papers
Official Statements
Publications
TIF Publications
Scientific Literature
Additional Resources
Media Centre
News
Newsletters
Events
Videos
Contact us
Search for
Home
/
ASCAT
ASCAT
News
October 27, 2020
Emerging Challenges & Future Therapies in Haemoglobinopathies The Focus of the ASCAT 2020 Conference
Read More »
Back to top button
Close
Search for
